Dactinomycin is an actinomycin used to treat a wide variety of cancers. A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus.
- Mechanism
- Curator reviewed
Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis.
- Primary indication
- For the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimenCurator reviewed · 7 structured indications
- Formula / weight
- C62H86N12O16 · 1255.417 g/mol (avg)
- First approval
- Canada, 2018 · United States, 1964
- Also known as
- 3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO- · ActD · Actinomycin C1 · Actinomycin D · ACTINOMYCIN I1
- Code names
- GNF-PF-2290 · NCI-C04682 · NSC-3053
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
RJURFGZVJUQBHK-IIXSONLDSA-NSMILES[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C1=C3N=C4C(OC3=C(C)C=C1)=C(C)C(=O)C(N)=C4C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]3([H])CCCN3C(=O)[C@H](NC1=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)CTargets
What you can answer from here — as of September 23, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
5TransportersSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Dactinomycin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account